Savara Inc (SVRA)
4.43
+0.10
(+2.31%)
USD |
NASDAQ |
Jul 05, 16:00
4.43
0.00 (0.00%)
After-Hours: 20:00
Savara Research and Development Expense (Annual): 44.26M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.26M |
| December 31, 2022 | 27.88M |
| December 31, 2021 | 28.99M |
| December 31, 2020 | 35.04M |
| December 31, 2019 | 38.78M |
| December 31, 2018 | 37.17M |
| December 31, 2017 | 18.51M |
| December 31, 2016 | 8.182M |
| December 31, 2015 | 4.321M |
| December 31, 2014 | 19.44M |
| December 31, 2013 | 12.90M |
| December 31, 2012 | 8.088M |
| Date | Value |
|---|---|
| December 31, 2011 | 5.758M |
| December 31, 2010 | 3.689M |
| December 31, 2009 | 6.508M |
| December 31, 2008 | 17.92M |
| December 31, 2007 | 15.93M |
| December 31, 2006 | 12.00M |
| December 31, 2005 | 8.682M |
| December 31, 2004 | 2.744M |
| December 31, 2003 | 0.749M |
| December 31, 2002 | 0.283M |
| December 31, 2001 | 0.9464M |
| December 31, 2000 | 1.017M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
27.88M
Minimum
2022
44.26M
Maximum
2023
34.99M
Average
35.04M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Madrigal Pharmaceuticals Inc | 272.35M |
| Aldeyra Therapeutics Inc | 29.46M |
| Akero Therapeutics Inc | 141.80M |
| 89bio Inc | 122.23M |
| Vigil Neuroscience Inc | 60.93M |